Topical Anesthetics: What the Pharmacology and the FDA Alerts Report

By Benn Bluestein-Veyra, M.Sc. Organic Chemistry · Updated 9 November 2026

ExaVeyra Sciences is a Miami-based B2B supplier of exosomes for topical aesthetic use to licensed clinics, and it works with a 503A compounding pharmacy that prepares formulations for licensed prescribers against individual prescriptions.

What this page covers, who can buy from ExaVeyra, and what is supplied
QuestionAnswer
What this page coversCompounded topical anesthetic pharmacology: how amide and ester agents block sodium channels, what governs skin absorption, and what FDA has warned.
Who can orderLicensed clinics and practitioners whose active professional license and NPI ExaVeyra has verified. Exosome orders also require a signed professional-use acknowledgment.
What ships, and howCompounded formulations are prepared and dispensed by our 503A pharmacy partner against a patient-specific prescription from the licensed prescriber and ship from the pharmacy. The pharmacy dispenses any controlled substance under its own DEA registration.

Topical anesthetics are amide local anesthetics (lidocaine, prilocaine) and ester local anesthetics (tetracaine, benzocaine) that block voltage-gated sodium channels after they cross the skin.[1][2][3] Since December 2006 FDA has warned that high concentrations of local anesthetics in compounded topical creams can cause seizures and irregular heartbeats, that the harm can increase with long contact, broad areas and covering, and that two deaths were connected to compounded topical anesthetic creams.[4] In 2018 FDA asked marketers of over-the-counter oral benzocaine products to relabel or discontinue them, and the same year the prescription labels carried a revised methemoglobinemia warning, as the Pliaglis record shows; in 2024 it issued warning letters and a press announcement on high-concentration lidocaine products sold without prescription for cosmetic procedures.[5][6][7]

Local anesthetics bind inside the sodium channel pore, and the amide or ester linkage sets how each is cleared

Fozzard and colleagues reviewed the molecular pharmacology in 2011: the local anesthetic binding site "has been localized to the inner pore of the channel, where drugs interact mainly with a phenylalanine in domain IV S6", drug affinity is "both voltage- and use-dependent", and the drugs "almost certainly also block by steric occlusion of the pore".[1] The approved lidocaine and prilocaine cream label states the same mechanism in label language: both agents "stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action."[2]

The amide and ester classes differ in their linkage and in their metabolism. The Pliaglis label describes lidocaine as "an amide-type local anesthetic agent" and tetracaine as "an ester-type local anesthetic agent", and it asks for caution in patients "with severe hepatic disease or pseudocholinesterase deficiency", which reflects hepatic clearance of the amide and plasma esterase hydrolysis of the ester.[3] Oni and colleagues measured lidocaine together with its hepatic metabolite monoethylglycinexylidide in serum after topical application, which is the amide pathway in practice, and in the Pliaglis pharmacokinetic studies tetracaine plasma levels were below the assay's limit of measurement.[3][8] The lidocaine and prilocaine cream label and the Pliaglis label carry the methemoglobinemia warning for the three prescription agents, and FDA's 2018 letter addresses benzocaine, which appears in over-the-counter monograph products.[2][3][5][9]

AgentClassWhere it appears in an approved topical labelLabel warning the source carries
LidocaineAmideLidocaine and prilocaine cream; Pliaglis (with tetracaine)Methemoglobinemia; overexposure with larger areas or longer times; additive cardiac effects with class III antiarrhythmics
PrilocaineAmideLidocaine and prilocaine creamMethemoglobinemia, with infants under six months named as more susceptible
TetracaineEsterPliaglis (with lidocaine)Methemoglobinemia; caution in pseudocholinesterase deficiency
BenzocaineEsterNo approved topical label cited; OTC oral and external analgesic monograph productsFDA 2018 letter: methemoglobinemia after a single exposure, including in adults

Absorption through skin depends on formulation, area, duration and occlusion, as the labels and the reviews describe it

The lidocaine and prilocaine cream label describes "a eutectic mixture" in which "both anesthetics are liquid at room temperature", formulated as an oil in water emulsion, and states that "the onset, depth and duration of dermal analgesia on intact skin" depend "primarily on the duration of application."[2] The Pliaglis label states that "the amount of lidocaine and tetracaine systemically absorbed from PLIAGLIS is directly related to both the duration of application and the surface area over which it is applied."[3] Kumar and colleagues reviewed the formulation levers: delivery "can be enhanced by using free bases; by increasing the drug concentration, lowering the melting point; by using physical and chemical permeation enhancers and lipid delivery vesicles."[10]

Sobanko, Miller and Alster reviewed topical anesthetics for dermatologic procedures in 2012 and identified "the amount of product used, body location, size of the surface area, and duration of product application" as factors to consider in reducing the risk of side effects, adding that "many case reports document adverse outcomes associated with the use of compounded products that the Food and Drug Administration has not approved that have inappropriately high anesthetic concentrations and from the use of topical anesthetics on excessively large skin surface areas during laser treatments."[11]

Oni, Brown and Kenkel applied five lidocaine-containing products, three sold over the counter and two compounded in a pharmacy, to the face and neck of 25 adults under occlusion for one hour and sampled serum over eight hours. The over-the-counter products produced the highest serum levels, interindividual variation was significant in every group but one, three adverse reactions occurred, and the authors concluded that "some individuals have unpredictably high absorption levels."[8] Marra and colleagues had earlier reported a woman with clinical systemic lidocaine toxicity and toxic-range serum levels after prolonged exposure to a high-concentration compounded lidocaine gel during fractional laser treatment, and proposed that laser disruption of the epidermal barrier combined with the concentration to produce the exposure.[12]

FDA's December 2006 warning letters describe two deaths connected to compounded topical anesthetic creams

The CDER Fiscal Year 2007 report records that on 4 December 2006 FDA issued warning letters to five compounding pharmacies, "advising these firms to stop compounding and distributing standardized versions of topical anesthetic creams which are marketed for general distribution rather than responding to the unique medical needs of individual patients."[4] It states that "exposure to high concentrations of local anesthetics, like those in compounded topical anesthetic creams, can cause grave reactions including seizures and irregular heartbeats" and that two deaths "have been connected to compounded topical anesthetic creams" made by two of the five pharmacies.[4]

The same report describes creams "often used to lessen pain in procedures such as laser hair removal, tattoos, and skin treatments" and containing "high doses of local anesthetics including lidocaine, tetracaine, benzocaine, and prilocaine."[4] FDA wrote that "when different anesthetics are combined into one product, each anesthetic's potential for harm is increased", that the harm "may also increase if the product is left on the body for long periods of time or applied to broad areas of the body, particularly if an area is then covered by a bandage, plastic, or other dressing", and that the risk "is even greater in small children, patients with pre-existing heart disease, and patients with severe liver disease."[4]

FDA has also issued public health advisories, which its 2024 warning letters cite by title: "Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures", "Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditions" and "Improper Use of Skin Numbing Products Can Be Deadly."[9][13] In its November 2024 letter FDA restated that it had "specifically warned" about caine-type products "applied over large areas of skin, particularly on irritated or broken skin, for prolonged periods of time, and when used in conjunction with methods that increase skin temperature such as warming the skin before application and/or covering the skin after application."[9]

The 2018 labeling revision placed a standardized methemoglobinemia warning in prescription topical anesthetic labels

FDA's letter of 21 May 2018 to marketers of over-the-counter oral benzocaine products states that the agency "estimates that more than 400 cases of benzocaine-associated methemoglobinemia occurring in the U.S. have been reported to FAERS and published in the medical literature since 1971", and that its most recent reviews found 119 cases between February 2009 and October 2017, four of them fatal, including a four-month-old infant.[5] The letter adds that "benzocaine-induced methemoglobinemia may occur after a single exposure and in persons who have previously been exposed to benzocaine without incident", and it asked firms to discontinue oral products marketed for teething or for children under two and to relabel the remaining oral health care products.[5]

FDA's Drug Safety-related Labeling Changes database records a supplement approved on 2 November 2018 that revised the Pliaglis label's Methemoglobinemia subsection to read: "Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition."[6] The warning adds that signs may be delayed some hours and that untreated methemoglobin levels can lead to "seizures, coma, arrhythmias, and death."[6] The current lidocaine and prilocaine cream label carries the identical text, and its Pediatric Use section asks that caregivers of infants under three months "limit the dose and area of application."[2]

The published record predates the labeling change. Guay summarized 242 episodes of local anesthetic-related methemoglobinemia in 2009, reported a discrepancy between pulse oximeter saturation and arterial oxygen partial pressure in 91.8 percent, noted that "a single spray of benzocaine may induce methemoglobinemia", and concluded that "benzocaine should no longer be used."[14] Chowdhary and colleagues identified 33 cases among 94,694 procedures over ten years at one academic center, a prevalence of 0.035 percent, with inpatient status a major risk factor and increased risk "with benzocaine-based anesthetics."[15] Shahid, Florez and Mbuagbaw pooled ten randomized trials of lidocaine and prilocaine cream in 907 infants under three months and reported little or no effect on venipuncture pain, a small-to-moderate rise in methemoglobin levels against placebo, and more skin blanching.[16]

FDA's 2024 press announcement and warning letters address high-concentration lidocaine products sold without prescription for cosmetic procedures

On 26 March 2024 FDA warned consumers not to use certain over-the-counter topical analgesics "marketed for topical use to relieve pain before, during or after certain cosmetic procedures, such as microdermabrasion, laser hair removal, tattooing and piercing", and issued warning letters to six companies.[7] The agency stated that some products contain lidocaine "at concentrations that are higher than what is permitted for over-the-counter, topical pain relief products", that increased absorption through the skin "may lead to serious injury such as irregular heartbeat, seizures and breathing difficulties", and that "FDA is not aware of evidence demonstrating these products are safe."[7] It asked consumers to keep to the permitted over-the-counter concentration, to avoid heavy application over large areas or on irritated or broken skin, and not to wrap treated skin, and it placed some companies on import alert.[7]

FDA's 25 March 2024 letter to one of the six companies states that "FDA is not aware of any adequate and well-controlled clinical studies in the published literature" supporting a finding that the named products are generally recognized as safe and effective.[13] On 15 November 2024 FDA wrote to a further company about a benzocaine, lidocaine and tetracaine cream sold "without a prescription", stating that the external analgesic monograph M017 "does not permit a combination of more than one '-caine' type active ingredient in a single drug product", that claims for "laser hair removal and tattoo removal treatments" go beyond the monograph's permitted indications, and that the product was therefore an unapproved new drug and misbranded.[9] These letters concern products sold over the counter, and FDA's stated concern is that use "before and/or during a cosmetic procedure may not always be supervised by trained health professionals."[9]

The systemic toxicity literature reports delayed presentations, events outside hospitals and defined at-risk groups

The American Society of Regional Anesthesia and Pain Medicine's third practice advisory, published in 2018 as an interim update of its 2010 advisory, reported that "contemporary case reports suggest a trend toward delayed presentation", that "small patient size and sarcopenia are additional factors that increase potential risk", and that "an increasing number of reported events occur outside of the traditional hospital setting and involve non-anesthesiologists."[17] Gitman and Barrington reviewed 47 cases described in 35 peer-reviewed articles between March 2014 and November 2016, most after nerve blocks or local infiltration: 22 patients were treated with intravenous lipid emulsion, two died, and seizure was the most common presenting feature at 53 percent of case reports.[18]

El-Boghdadly, Pawa and Chin reported that "although neurological presentation is most common, LAST often presents atypically, and one-fifth of the reported cases present with isolated cardiovascular disturbance", and that the mechanisms are "multifactorial, with diverse cellular effects in the central nervous system and cardiovascular system."[19] Macfarlane and colleagues wrote in 2021 that cases involving providers outside anesthesia are increasing and named the at-risk groups as "those at the extremes of age; patients with cardiac, hepatic and specific metabolic diseases; and those who are pregnant."[20] The American Academy of Dermatology's 2016 guideline on local anesthesia in office-based dermatologic surgery, built on "the best evidence available as well as expert opinion", addresses the use and safety of local anesthesia for office-based dermatologic procedures.[21] The treatment literature is specific: El-Boghdadly and colleagues named "early administration of lipid emulsion therapy, prompt seizure management, and careful selection of cardiovascular supportive pharmacotherapy" as the key advances, and the labels state that severe methemoglobinemia "may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen."[2][19]

  • The lidocaine and prilocaine label asks for "close surveillance" and consideration of ECG monitoring in patients on class III antiarrhythmic drugs, "because cardiac effects may be additive."[2]
  • The Pliaglis label asks prescribers to "consider total amount of local anesthetics absorbed from all formulations" and not to apply to mucous membranes or broken or inflamed skin.[3]
  • Both labels state that application to larger areas or for longer times than labeled "could result in" absorption sufficient for serious adverse effects.[2][3]

Section 503A governs the compounded preparation, and FDA distinguishes patient-specific compounding from standardized distribution

Section 503A permits a licensed pharmacist to compound a drug product using bulk drug substances that "comply with the standards of an applicable United States Pharmacopoeia or National Formulary monograph, if a monograph exists, and the United States Pharmacopoeia chapter on pharmacy compounding" or, failing a monograph, "are drug substances that are components of drugs approved by the Secretary", manufactured by an establishment registered with FDA and "accompanied by valid certificates of analysis for each bulk drug substance."[22] Lidocaine, prilocaine and tetracaine are components of FDA-approved drugs, including the two labels cited here, so none of the three depends on the 503A bulks list.[2][3] The statute also conditions the exemption on a compounder who "does not compound regularly or in inordinate amounts" drug products "that are essentially copies of a commercially available drug product."[22]

FDA states plainly that "compounded drugs are not FDA-approved", which "means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."[23] Its 2007 account of the topical anesthetic letters draws the line: traditional compounding follows "a physician's decision that his or her patient has a special medical need that cannot be met by FDA-approved drugs", "FDA's action did not target this practice", and the concern was that the five firms "were behaving like drug manufacturers, not traditional compounding pharmacies, because they produced standardized versions of topical anesthetic creams for general distribution."[4]

ExaVeyra's compounded topical anesthetic preparations reach a practice through a licensed 503A pharmacy partner on a patient-specific prescription, and the partner supplies a certificate of analysis for each lot of bulk substance on request. The composition the prescription specifies, whether a compounded preparation or an approved product fits the patient, and the area, duration and occlusion conditions under which it is applied are the practitioner's decisions, made against the labels, the advisories and the literature reported here. A practice that wants to review compounded topical anesthetic options can start from the topical numbing catalog page and request the certificate of analysis for any lot before ordering.

This article summarizes publicly available federal regulation for licensed practitioner education. It is not legal advice, medical advice, or regulatory guidance, and it does not establish that any particular product or practice is compliant. Confirm current federal and state obligations with qualified counsel.

Annotated References

Numbered in the order they are cited in the text. Each source is annotated with what it supports on this page; peer-reviewed articles are listed with journal, volume, issue and pages, and primary sources are regulations, agency documents, guidelines and position statements.

  1. 1.Peer-reviewedFozzard HA, Sheets MF, Hanck DA. The sodium channel as a target for local anesthetic drugs. Frontiers in Pharmacology. 2011;2:68. https://pubmed.ncbi.nlm.nih.gov/22053156/Annotation: The inner-pore binding site at the domain IV S6 phenylalanine, voltage- and use-dependent affinity, and steric block of the pore.
  2. 2.Official sourceDailyMed (NIH National Library of Medicine), Lidocaine and Prilocaine Cream prescribing information, E. Fougera and Co. (label effective 15 October 2026). Accessed 8 November 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=833cd52c-6470-49c4-937f-1393971f4db9
  3. 3.Official sourceDailyMed (NIH National Library of Medicine), Pliaglis (lidocaine and tetracaine) cream prescribing information (label effective 9 March 2026). Accessed 8 November 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d854faa5-0af8-4684-b5cd-a0b8a91fb7cd
  4. 4.RegulatoryFDA, Center for Drug Evaluation and Research, Fiscal Year 2007 report, Chapter 3: FDA Issues Warning Letters to Five Firms Compounding Topical Anesthetic Creams (pages 3-18 to 3-20). Accessed 8 November 2026. https://www.fda.gov/files/about%20fda/published/Chapter-3--Center-for-Drug-Evaluation-and-Research-(CDER)-2007.pdf
  5. 5.RegulatoryFDA, Letter regarding over-the-counter oral health care drug products containing benzocaine (21 May 2018). Accessed 8 November 2026. https://www.fda.gov/files/drugs/published/FDA-Letter-Regarding-Benzocaine.pdf
  6. 6.RegulatoryFDA, Drug Safety-related Labeling Changes (SrLC): Pliaglis, supplement 11 approved 2 November 2018, Warnings and Precautions 5.1 Methemoglobinemia. Accessed 8 November 2026. https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=1371
  7. 7.RegulatoryFDA, FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects (press announcement, 26 March 2024). Accessed 8 November 2026. https://www.fda.gov/news-events/press-announcements/fda-warns-consumers-avoid-certain-topical-pain-relief-products-due-potential-dangerous-health
  8. 8.Peer-reviewedOni G, Brown S, Kenkel J. Comparison of five commonly-available, lidocaine-containing topical anesthetics and their effect on serum levels of lidocaine and its metabolite monoethylglycinexylidide (MEGX). Aesthetic Surgery Journal. 2012;32(4):495-503. https://pubmed.ncbi.nlm.nih.gov/22452841/Annotation: Serum lidocaine and MEGX after one hour of occluded facial application of three over-the-counter and two compounded products in 25 adults: highest levels with the OTC products, significant interindividual variation, three adverse reactions.
  9. 9.RegulatoryFDA, Warning Letter to Centura Pharmaceuticals Inc, MARCS-CMS 684733 (15 November 2024). Accessed 8 November 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/centura-pharmaceuticals-inc-684733-11152024
  10. 10.Peer-reviewedKumar M, Chawla R, Goyal M. Topical anesthesia. Journal of Anaesthesiology Clinical Pharmacology. 2015;31(4):450-456. https://pubmed.ncbi.nlm.nih.gov/26702198/Annotation: The formulation levers that increase delivery (free bases, concentration, melting point, permeation enhancers, lipid vesicles) and the attention to area, duration, age and weight.
  11. 11.Peer-reviewedSobanko JF, Miller CJ, Alster TS. Topical anesthetics for dermatologic procedures: a review. Dermatologic Surgery. 2012;38(5):709-721. https://pubmed.ncbi.nlm.nih.gov/22243434/Annotation: The factors governing side effects (amount, body location, surface area, duration) and the case reports of adverse outcomes with unapproved compounded products at high concentrations and over large areas.
  12. 12.Peer-reviewedMarra DE, Yip D, Fincher EF, Moy RL. Systemic toxicity from topically applied lidocaine in conjunction with fractional photothermolysis. Archives of Dermatology. 2006;142(8):1024-1026. https://pubmed.ncbi.nlm.nih.gov/16924052/Annotation: A woman with clinical systemic lidocaine toxicity and toxic-range serum levels after prolonged exposure to a high-concentration compounded lidocaine gel during fractional laser treatment.
  13. 13.RegulatoryFDA, Warning Letter to Dermal Source, Inc., MARCS-CMS 663632 (25 March 2024). Accessed 8 November 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dermal-source-inc-663632-03252024
  14. 14.Peer-reviewedGuay J. Methemoglobinemia related to local anesthetics: a summary of 242 episodes. Anesthesia and Analgesia. 2009;108(3):837-845. https://pubmed.ncbi.nlm.nih.gov/19224791/Annotation: 242 published episodes: the pulse oximetry discrepancy in 91.8 percent, methemoglobinemia after a single benzocaine spray, the complications, and the conclusion that benzocaine should no longer be used.
  15. 15.Peer-reviewedChowdhary S, Bukoye B, Bhansali AM, Carbo AR, Adra M, Barnett S, Aronson MD, Leffler DA. Risk of topical anesthetic-induced methemoglobinemia: a 10-year retrospective case-control study. JAMA Internal Medicine. 2013;173(9):771-776. https://pubmed.ncbi.nlm.nih.gov/23546303/Annotation: 33 cases of procedure-related methemoglobinemia among 94,694 procedures over ten years (prevalence 0.035 percent), with inpatient status and benzocaine-based anesthetics as risk factors.
  16. 16.Peer-reviewedShahid S, Florez ID, Mbuagbaw L. Efficacy and Safety of EMLA Cream for Pain Control Due to Venipuncture in Infants: A Meta-analysis. Pediatrics. 2019;143(1):e20181173. https://pubmed.ncbi.nlm.nih.gov/30587535/Annotation: Ten randomized trials in 907 infants under three months: little or no effect on venipuncture pain, a small-to-moderate rise in methemoglobin against placebo, and more skin blanching.
  17. 17.Peer-reviewedNeal JM, Barrington MJ, Fettiplace MR, Gitman M, Memtsoudis SG, Mörwald EE, Rubin DS, Weinberg G. The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity: Executive Summary 2017. Regional Anesthesia and Pain Medicine. 2018;43(2):113-123. https://pubmed.ncbi.nlm.nih.gov/29356773/Annotation: The ASRA interim update: lipid resuscitation mechanisms, the trend toward delayed presentation, small patient size and sarcopenia as risk factors, and events outside hospitals involving non-anesthesiologists.
  18. 18.Peer-reviewedGitman M, Barrington MJ. Local Anesthetic Systemic Toxicity: A Review of Recent Case Reports and Registries. Regional Anesthesia and Pain Medicine. 2018;43(2):124-130. https://pubmed.ncbi.nlm.nih.gov/29303925/Annotation: 47 published cases of local anesthetic systemic toxicity between March 2014 and November 2016: 22 treated with lipid emulsion, two deaths, seizure the most common presenting feature.
  19. 19.Peer-reviewedEl-Boghdadly K, Pawa A, Chin KJ. Local anesthetic systemic toxicity: current perspectives. Local and Regional Anesthesia. 2018;11:35-44. https://pubmed.ncbi.nlm.nih.gov/30122981/Annotation: Multifactorial mechanisms, atypical and isolated cardiovascular presentations in one-fifth of reported cases, and the treatment advances the review names.
  20. 20.Peer-reviewedMacfarlane AJR, Gitman M, Bornstein KJ, El-Boghdadly K, Weinberg G. Updates in our understanding of local anaesthetic systemic toxicity: a narrative review. Anaesthesia. 2021;76 Suppl 1:27-39. https://pubmed.ncbi.nlm.nih.gov/33426662/Annotation: The rising share of cases involving providers outside anesthesia and the at-risk groups: extremes of age, cardiac, hepatic and metabolic disease, and pregnancy.
  21. 21.Peer-reviewedKouba DJ, LoPiccolo MC, Alam M, Bordeaux JS, Cohen B, Hanke CW, Jellinek N, Maibach HI, Tanner JW, Vashi N, Gross KG, Adamson T, Begolka WS, Moyano JV. Guidelines for the use of local anesthesia in office-based dermatologic surgery. Journal of the American Academy of Dermatology. 2016;74(6):1201-1219. https://pubmed.ncbi.nlm.nih.gov/26951939/Annotation: The American Academy of Dermatology evidence-based guideline on the use and safety of local anesthesia for office-based dermatologic procedures.
  22. 22.Regulatory21 U.S.C. 353a, Pharmacy compounding (United States Code, 2024 edition, GPO). Accessed 8 November 2026. https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353a.htm
  23. 23.RegulatoryFDA, Compounding and the FDA: Questions and Answers (content current as of 16 September 2025). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Cite this page

ExaVeyra Sciences Editorial Team. Topical Anesthetics: Pharmacology and Alerts. ExaVeyra Sciences; 9 November 2026. Available from: https://exaveyra.com/science/compounds/topical-anesthetics-pharmacology-and-alerts. Accessed [date accessed].

ExaVeyra Exclusive Member Resources

For verified and approved practicesReserved for clinicians

Research Vault

Curated peer-reviewed literature for each catalog compound, with a printable two-minute brief, evidence at a glance and the papers to start with.

  • 266 peer-reviewed papers, each with its DOI or PubMed link
  • 8 research areas
  • 128 systematic reviews, meta-analyses and randomized trials
  • 18 compounds with a two-minute brief

Registration takes about two minutes. Access opens after NPI verification and a review by our team. No payment details.

Each brief opens with the strongest study designs first, then the newest.

Common questions

What distinguishes amide from ester topical anesthetics?
Lidocaine and prilocaine are amide local anesthetics and tetracaine and benzocaine are esters, as the approved labels describe them. Both classes block voltage-gated sodium channels from inside the pore. Amides are cleared mainly by the liver, which is why the labels ask for caution in severe hepatic disease, and esters are hydrolyzed by plasma pseudocholinesterase, which is why the Pliaglis label names pseudocholinesterase deficiency.
What did FDA say about compounded topical anesthetic creams in 2006 and 2007?
On 4 December 2006 FDA issued warning letters to five compounding pharmacies producing standardized topical anesthetic creams for general distribution. The CDER Fiscal Year 2007 report connects two deaths to creams from two of those pharmacies and describes the hazard as high concentrations of combined anesthetics left on large or covered areas for long periods. FDA has also issued public health advisories on skin numbing products for cosmetic procedures and for mammography, which its 2024 warning letters still cite by title.
What did the 2018 FDA action on methemoglobinemia require?
FDA asked marketers of over-the-counter oral benzocaine products to stop selling products marketed for teething or for children under two and to relabel the others, and the Pliaglis prescription label received a revised methemoglobinemia warning approved on 2 November 2018, which the current lidocaine and prilocaine cream label carries word for word.
What did FDA's 2024 warning letters on topical anesthetics address?
The 26 March 2024 press announcement and six warning letters concerned over-the-counter products marketed for cosmetic procedures, some labeled with lidocaine above the concentration permitted for OTC topical pain relief products. A further letter on 15 November 2024 addressed a benzocaine, lidocaine and tetracaine cream sold without a prescription, stating that the monograph does not permit more than one caine-type active ingredient in a single OTC product and that cosmetic-procedure claims fall outside it. The letters concern OTC products, and FDA's stated concern is unsupervised application.
What governs how much topical anesthetic is absorbed through the skin?
The approved labels and the reviews name the same variables: the concentration and formulation, the surface area, the duration of contact, occlusion or heat after application, and the condition of the skin. Oni and colleagues found unpredictably high absorption in some individuals even with over-the-counter products, and Marra and colleagues reported systemic toxicity when a high-concentration compounded gel was combined with laser disruption of the skin barrier.
How does a compounded topical anesthetic fit under section 503A?
Lidocaine, prilocaine and tetracaine are components of approved drugs, so a 503A pharmacy may compound them from bulk substances that meet the statute's monograph, registration and certificate of analysis conditions, for an identified patient on a prescription. FDA's 2007 account of the topical anesthetic letters states that its action did not target compounding on a physician's decision that a patient has a special medical need, and that the concern was standardized versions produced for general distribution.

This page is provided for informational purposes only. It is not medical advice, it is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for the judgment of a licensed practitioner. Consult a healthcare professional before acting on anything stated here. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. These references report what trials, reviews, product labels and FDA communications state about compounds that a 503A pharmacy partner prepares, for professional education, and make no statement about the suitability of any product for any patient. Where this page discusses an FDA-approved product, the approved labeling governs and nothing here modifies it. Compounded preparations are a separate product class: they are not FDA-approved finished drug products, they are prepared under section 503A of the Federal Food, Drug, and Cosmetic Act against a patient-specific prescription, and they are prescription products supplied to licensed practitioners only. Cosmetic ingredients discussed here are described within the cosmetic regulatory frame and are not drugs. The prescribing decision rests with the licensed practitioner. Read the full notice

Reference only. Not legal or medical advice.

The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.

Read the full notice